Login to Your Account

Myriad Halts Flurizan Program on Phase III Alzheimer's Miss

By Tiffany Turner

Tuesday, July 1, 2008
Shares of Myriad Genetics Inc. fell 5 percent in Monday trading on news that the company's Act-Earli-AD trial, a pivotal 18-month Phase III study of Flurizan (tarenflurbil) in patients with mild Alzheimer's disease (AD), did not achieve statistical significance on either of its primary endpoints - cognition and activities of daily living. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription